Under the supervision of Sylvaine You, team Immune-Endocrine Cross-Talk in Diabetes
Abstract:
Type 1 diabetes (T1D) and allergy result from a breakdown of immune tolerance, leading to pathogenic responses directed against defined antigens. Antigen-specific immunotherapies could selectively restore this tolerance without inducing broad immunosuppression. However, their efficacy remains limited by poor antigen bioavailability, insufficiently optimised administration strategies and, in T1D, the progressive diversification of autoimmune targets. This thesis evaluated an intranasal platform comprising antigens fused to the fragment crystallisable (Fc) region of immunoglobulin G subclass 1 (IgG1). This platform was designed to exploit the neonatal Fc receptor (FcRn), enhance mucosal antigen transport and promote regulatory immune responses. Two complementary insulin-centred settings were investigated: the desensitisation of an established allergy and the prevention of spontaneous T1D.
Following the development of an insulin-allergy model in non-obese diabetic (NOD) mice lacking the insulin 2 gene (Ins2), designated NOD.Ins2−/− mice, intranasal administration of preproinsulin fused to the Fc region (PPI-Fc) proved more effective than native insulin or subcutaneous administration in reducing the local allergic reaction, total and insulin-specific immunoglobulin E (IgE) levels, mast-cell activation and T helper type 2 (Th2) responses. PPI-Fc increased the abundance of regulatory T cells (Tregs) expressing the forkhead box P3 transcription factor (Foxp3+), as well as their production of interleukin 10 (IL-10) and their suppressive capacity. It also induced the in vivo peripheral conversion of conventional T cells into Tregs. Blockade of the IL-10 receptor abolished most of this protection, demonstrating the essential role of this pathway. Desensitisation persisted after treatment cessation. The lack of effect of an irrelevant Fc-fused antigen in this model, followed by the efficacy of ovalbumin fused to Fc (ovalbumin-Fc) in a model of cutaneous ovalbumin allergy, confirmed the antigen specificity and modularity of the approach.
In the T1D model, high-dose PPI-Fc monotherapy only transiently delayed disease onset without reducing final disease incidence. To broaden antigenic coverage, PPI-Fc was combined with a multiepitope polypeptide fused to Fc (PoPe-Fc), containing three diabetogenic epitopes recognised by cluster of differentiation 4-positive (CD4+) and cluster of differentiation 8-positive (CD8+) T cells. The PPI-Fc/PoPe-Fc combination reproducibly delayed diabetes onset and maintained 50–60% of NOD mice diabetes-free up to 35 weeks of age across three independent experiments. PoPe-Fc monotherapy also prolonged diabetes-free survival, protecting 40–42.9% of the mice, although synergy with PPI-Fc could not be formally established. PPI-Fc and PoPe-Fc bound to murine FcRn, reached the circulation after intranasal administration through a largely FcRn-dependent mechanism, and were processed and presented to autoreactive T cells.
In exploratory analyses, protected animals showed reduced insulin-specific interferon gamma (IFN-γ) responses in pancreatic lymph nodes, increased IL-10 production in cervical and pancreatic lymph nodes, and increased numbers of Foxp3+ Tregs in pancreatic lymph nodes following combination treatment. This work provides proof of concept for an intranasal Fc-fused antigen platform capable of redirecting pathogenic allergic or autoimmune responses towards a regulatory profile. It demonstrates that efficacy depends on the appropriateness and breadth of antigenic coverage and supports further optimisation of the constructs, doses and administration regimens before clinical translation.
Keywords: Type 1 diabetes, insulin allergy, antigen-specific immunotherapy, intranasal administration, Fc-fused antigens, preproinsulin-Fc (PPI-Fc), neonatal Fc receptor (FcRn), immune tolerance, regulatory T cells (Tregs), interleukin-10 (IL-10)